Summary & Overview
HCPCS Level II J0714: Injection, ceftazidime and avibactam, 0.5 g/0.125 g
HCPCS Level II code J0714 designates the injectable combination drug ceftazidime and avibactam (0.5 g/0.125 g per unit). This code is used to bill for the medication component of intravenous antibiotic therapy and is important for hospitals, infusion centers, and outpatient clinics managing serious Gram-negative infections, including those caused by resistant organisms. Nationally, accurate use of this code affects drug utilization tracking, payer reimbursement, and antimicrobial stewardship reporting.
Key payers in scope include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise clinical context for the drug, the likely sites of service where billing will occur, and an outline of which payers are typically involved in coverage decisions. The publication summarizes available benchmarks and policy-relevant considerations around billing and coding for high-cost infused antibiotics, highlights common modifier usage patterns where applicable, and notes areas where payer policy language or prior authorization requirements commonly influence utilization. Sections also cover coding nuances, claims-line implications, and references to related billing topics.
Data not available in the input is noted where payer-specific policies, associated taxonomies, ICD-10 diagnoses, and related billing codes would normally be detailed.
Billing Code Overview
HCPCS Level II code J0714 represents an injection of ceftazidime and avibactam, 0.5 g/0.125 g. This code describes the drug product and unit of measure used for administration of the combination antibiotic-cephalosporin with beta-lactamase inhibitor.
Service Type: Drug administration (intravenous infusion or injection)
Typical Site of Service: Hospital inpatient or outpatient infusion center, emergency department, or other outpatient clinic settings where intravenous antibiotics are administered
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is a hospitalized adult with a documented or suspected complicated Gram-negative bacterial infection, such as hospital-acquired or ventilator-associated pneumonia, complicated intra-abdominal infection, or complicated urinary tract infection caused by multidrug-resistant organisms. The patient often has failed prior empiric therapy or has culture results showing organisms producing extended-spectrum beta-lactamases or carbapenemases. Ceftazidime-avibactam is administered intravenously; preparation and dose are based on the J0714 unit of 0.5 g/0.125 g, with total daily dose and frequency determined by the treating infectious disease physician and pharmacy. Typical workflow: assessment and indications confirmed by the physician; order placed in the electronic health record with dosing and duration; pharmacy compounds and dispenses the medication; nursing performs IV administration (often via peripheral or central line); therapeutic monitoring occurs with assessment of renal function for dose adjustment, culture and sensitivity follow-up, and documentation of response and adverse events (for example, allergic reaction or Clostridioides difficile infection). Typical sites of service include inpatient acute care hospitals, long-term acute care hospitals, observation units, and skilled nursing facilities providing IV antibiotic therapy.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | Default billing indicator (no modifier) |